PatenSee

Company Overview

Snapshot

Founded in March 2019 by Gal Goshen, Oz Seadia, and Hagay Drori, PatenSee operates with 11–50 employees. The company has raised $2.35M across two funding rounds from four investors. In September 2025, PatenSee received FDA Breakthrough Device Designation for its non-contact vascular access management system for hemodialysis patients.

Business overview

PatenSee is a clinical-stage medical device company specializing in a contactless surveillance system for the early detection of asymptomatic vascular stenosis in hemodialysis patients. The company leverages advanced multimodal imaging technologies and machine learning to identify stenosis risk at its earliest stages, enabling timely interventions to protect patient hemodialysis lifelines. PatenSee operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Digital Healthcare, targeting hospitals and healthcare providers with its B2B business model.

Strategic signal

PatenSee's receipt of FDA Breakthrough Device Designation in September 2025 for its non-contact vascular access management system is a significant validation of its technology. This designation indicates the FDA's recognition of the device's potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions, signaling strong regulatory confidence and a clear path toward accelerated market access for investors.

Company Intelligence Q&A

What is PatenSee's core technology?

PatenSee develops a contactless surveillance system that utilizes advanced multimodal imaging technologies and machine learning to detect early asymptomatic vascular stenosis in hemodialysis patients.

When did PatenSee receive FDA Breakthrough Device Designation?

In September 2025, PatenSee announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for its non-contact vascular access management system for patients undergoing hemodialysis.

What was the outcome of PatenSee's clinical trial at Rabin Medical Center?

In March 2022, PatenSee announced successful clinical trial results at Rabin Medical Center, demonstrating the promise of its contactless imaging device in timely and accurately monitoring dialysis patients.

Which organizations participated in PatenSee's initial funding round?

In March 2019, PatenSee received funding from investors including Israel Innovation Authority.

When did PatenSee initiate its first in-human trial?

In February 2021, PatenSee initiated its first in-human trial with its contactless imaging surveillance system for patients undergoing hemodialysis.